The Monoclonal Antibodies Campath-1H and Rituximab in theTherapy of Chronic Lymphocytic Leukemia

Publisher： Karger

E-ISSN： 2296-5262|23|6|526-532

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.6, 2001-01, pp. : 526-532

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fludarabine, cyclophosphamide, and multiple‐dose rituximab as frontline therapy for chronic lymphocytic leukemia

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3869-3876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab Therapy in Cutaneous Infiltration of Chronic Lymphocytic Leukaemia

By  

Acta Haematologica, Vol. 130, Iss. 1, 2013-02 ,pp. : 47-51

Karger

Access to resources Recommend Favorite

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3805-3811

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

By  

Oncology Research and Treatment, Vol. 39, Iss. 1-2, 2016-0 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 103-104

Karger

Access to resources Recommend Favorite